Home › Research › TREM2 and immune genetics
Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis
Liu D, Cao B, Zhao Y, Huang H, McIntyre RS, Rosenblat JD, Zhou H.. Neuroscience letters, 2018-08-29
Topic: Amyloid, tau and blood-test diagnosis
Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential and novel biomarker of neuroinflammation implicated in the onset and progression of Alzheimer's disease (AD). However, previous studies evaluating levels of sTREM2 in different clinical stages of AD have yielded inconsistent results. To clarify the dynamic change of sTREM2 in AD progression, we conducted a meta-analysis of case-control and cohort studies to determine the role of cerebral spinal fluid (CSF) and plasma sTREM2 levels in preclinical AD (pre-AD), mild cognitive impairment (MCI) and AD dementia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, D., Cao, B., Zhao, Y., Huang, H., McIntyre, R. S., Rosenblat, J. D., et al. (2018). Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. Neuroscience letters. https://doi.org/10.1016/j.neulet.2018.08.038
Vancouver
Liu D, Cao B, Zhao Y, Huang H, McIntyre RS, Rosenblat JD, et al. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. Neuroscience letters. 2018. doi:10.1016/j.neulet.2018.08.038. PMID: 30171911.
BibTeX
@article{liu2018-30171911,
author = {Liu, D. and Cao, B. and Zhao, Y. and Huang, H. and McIntyre, R. S. and Rosenblat, J. D. and Zhou, H.},
title = {{Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis}},
journal = {Neuroscience letters},
year = {2018},
doi = {10.1016/j.neulet.2018.08.038},
pmid = {30171911},
url = {https://doi.org/10.1016/j.neulet.2018.08.038}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- However, previous studies evaluating levels of sTREM2 in different clinical stages of AD have yielded inconsistent results.
- To clarify the dynamic change of sTREM2 in AD progression, we conducted a meta-analysis of case-control and cohort studies to determine the role of cerebral spinal fluid (CSF) and plasma sTREM2 levels in preclinical AD (pre-AD), mild cognitive impairment (MCI) and AD dementia.
- We searched PubMed, MEDLINE, EMBASE, the Cochrane Library for English articles and Sinomed, CNKI for Chinese.
- The associations between sTREM2 levels and AD continuum groups (pre-AD, MCI and AD) were analyzed.
Why it matters
This meta-analysis pooled studies of soluble TREM2 levels in spinal fluid and blood across stages of Alzheimer's disease. It examines a possible biomarker and does not show that any treatment prevents or cures Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designmeta-analysis
- Participants82
- Evidence strengthHigh
How this study scored 63/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuroscience letters) |
| Journal's citation record | 3 / 4 | Neuroscience Letters: journal h-index 267 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 82 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 4 / 7 | Cited 88 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.8 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Hui Zhou: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Peking University: institution h-index 1,098 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30171911) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.